Experience > Select Research Publications
Osarogiagbon RU, Rami-Porta R, Tsao MS, Montuenga LM, Nishimura KK, Giroux DJ , Travis W, Asamura H, Rusch V, Carbone DP, Hirsch FR. The International Association for the Study of Lung Cancer Molecular Database Project: Objectives, Challenges, and Opportunities. J Thorac Oncol. 2021 Jun;16(6):897-901. doi: 10.1016/j.jtho.2021.03.003. Epub 2021 Mar 23. PMID: 33771657; PMCID: PMC8159848.
Kizub DA, Miao J, Schubert MM, Paterson AHG, Clemons M, Dees EC, Ingle JN, Falkson CI, Barlow WE, Hortobagyi GN, Gralow JR. Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307). Support Care Cancer. 2021 May;29(5):2509-2517. doi: 10.1007/s00520-020-05748-8. Epub 2020 Sep 15. PMID: 32929540; PMCID: PMC7956914.
Boyle EM, Rosenthal A, Wang Y, Farmer P, Rutherford M, Ashby C, Bauer M, Johnson SK, Wardell CP, Hoering A, Schinke C, Thanendrarajan S, Zangari M, Barlogie B, Davies FE, Walker BA, van Rhee F, Morgan GJ. High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. Br J Haematol. 2021 Jul 9. doi: 10.1111/bjh.17670. Epub ahead of print. PMID: 34244996.
Boyle EM, Rosenthal A, Ghamlouch H, Wang Y, Farmer P, Rutherford M, Ashby C, Bauer M, Johnson SK, Wardell CP, Wang Y, Hoering A, Schinke C, Thanendrarajan S, Zangari M, Barlogie B, Dhodapkar MV, Davies FE, Morgan GJ, van Rhee F, Walker BA. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. Leukemia. 2021 Aug 7. doi: 10.1038/s41375-021-01379-y. Epub ahead of print. PMID: 34365473.
Paoletti C, Barlow WE, Cobain EF, Bergqvist M, Mehta RS, Gralow JR, Hortobagyi GN, Albain KS, Pusztai L, Sharma P, Godwin AK, Thompson AM, Hayes DF, Rae JM. Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial. Clin Cancer Res. 2021 Sep 14:clincanres.1562.2021. doi: 10.1158/1078-0432.CCR-21-1562. Epub ahead of print. PMID: 34521624.
Piccart MJ, Kalinsky K, Gray R, Barlow WE, Poncet C, Cardoso F, Winer E, Sparano J. Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust. Ann Oncol. 2021 Sep;32(9):1077-1082. doi: 10.1016/j.annonc.2021.05.804. Epub 2021 May 31. PMID: 34082017.
Durie BGM, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, Dispenzieri A, Kahanic SP, Thakuri MC, Reu FJ, Reynolds CM, Orlowski RZ, Barlogie B. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020 May 11;10(5):53. doi: 10.1038/s41408-020-0311-8. PMID: 32393732
Nishimura K, Barlogie B, van Rhee F, Zangari M, Walker BA, Rosenthal A, Schinke C, Thanendrarajan S, Davies FE, Hoering A, Morgan GJ. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Adv. 2020 Jan 28;4(2):422-431. doi: 10.1182/bloodadvances.2019000524. PMID: 31990333
Boyle EM, Ashby C, Tytarenko RG, Deshpande S, Wang H, Wang Y, Rosenthal A, Sawyer J, Tian E, Flynt E, Hoering A, Johnson SK, Rutherford MW, Wardell CP, Bauer MA, Dumontet C, Facon T, Thanendrarajan S, Schinke CD, Zangari M, van Rhee F, Barlogie B, Cairns D, Jackson G, Thakurta A, Davies FE, Morgan GJ, Walker BA. BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clin Cancer Res. 2020 May 15;26(10):2422-2432. doi: 10.1158/1078-0432.CCR-19-1507. Epub 2020 Jan 27. PMID: 31988198
Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan G. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019 Jan;33(1):159-170. doi: 10.1038/s41375-018-0196-8. Epub 2018 Jul 2. PMID: 29967379
Usmani SZ, Hoering A, Cavo M, Miguel JS, Goldschimdt H, Hajek R, Turesson I, Lahuerta JJ, Attal M, Barlogie B, Lee JH, Kumar S, Lenhoff S, Morgan G, Rajkumar SV, Durie BGM, Moreau P. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project. Blood Cancer J. 2018 Nov 23;8(12):123. doi: 10.1038/s41408-018-0155-7. PMID: 30470751
Ailawadhi S, Jacobus S, Sexton R, Stewart AK, Dispenzieri A, Hussein MA, Zonder JA, Crowley J, Hoering A, Barlogie B, Orlowski RZ, Rajkumar SV. Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J. 2018 Jul 6;8(7):67. doi: 10.1038/s41408-018-0102-7. PMID: 29980678
Feczko AF, Wang H, Nishimura K, Farivar AS, Bograd AJ, Vallières E, Aye RW, Louie BE. Proficiency of Robotic Lobectomy Based on Prior Surgical Technique in The Society of Thoracic Surgeons General Thoracic Database. Ann Thorac Surg. 2019 Oct;108(4):1013-1020. doi: 10.1016/j.athoracsur.2019.04.046. Epub 2019 Jun 5. PMID: 31175871
Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan GJ. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018 Aug 9;132(6):587-597. doi: 10.1182/blood-2018-03-840132. Epub 2018 Jun 8. PMID: 29884741
Davies FE, Rosenthal A, Rasche L, Petty NM, McDonald JE, Ntambi JA, Steward DM, Panozzo SB, van Rhee F, Zangari M, Schinke CD, Thanendrarajan S, Walker B, Weinhold N, Barlogie B, Hoering A, Morgan GJ. Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. Haematologica. 2018 Jun;103(6):1047-1053. doi: 10.3324/haematol.2017.177139. Epub 2018 Mar 22. PMID: 29567784
Schinke C, Qu P, Mehdi SJ, Hoering A, Epstein J, Johnson SK, van Rhee F, Zangari M, Thanendrarajan S, Barlogie B, Davies FE, Yaccoby S, Morgan GJ. The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma. Clin Cancer Res. 2018 Jun 15;24(12):2913-2919. doi: 10.1158/1078-0432.CCR-17-2627. Epub 2018 Mar 21. PMID: 29563136
Heinrich M, Rankin C, Blanke CD, Demetri GD, Borden EC, Ryan CW, von Mehren M, Blackstein ME, Priebat DA, Tap WD, Maki RG, Corless CL, Fletcher JA, Owzar K, Crowley JJ, Benjamin RS, Baker LH. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors with Next-Generation Sequencing Results Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol. Published online February 09, 2017. doi:10.1001/jamaoncol.2016.6728. PMID: 28196207. https://www.ncbi.nlm.nih.gov/pubmed/?term=28196207
Valdivieso M, Bussalleu A, Sexton R, Thompson KC, Osorio S, Novoa Reyes, I, Crowley JJ, Baker LH, Xi C. Antibiotic resistance among Helicobacter pylori clinical isolates in Lima, Peru. Infection and Drug Resistance. 2017 March; 2017(10):85-90. PMID: 28331349. https://www.ncbi.nlm.nih.gov/pubmed/?term=28331349
Hoering A, Durie B, Wang H, Crowley J. End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.Future Oncol. 2017 Apr 11.
Matsui S, Noma H, Qu P, Sakai Y, Matsui K, Heuck C, Crowley J. Multi-subgroup gene screening using semi-parametric hierarchical mixture models and the optimal discovery procedure: Application to a randomized clinical trial in multiple myeloma.Biometrics. 2017 May 12.
Chansky K, Detterbeck FC, Andrew G Nicholson AG, Valerie Rusch W, Vallières E, Groome P, Kennedy C, Krasnik M, Peak M, Shemanski L, Bolejack V, Crowley JJ, Asamura H, Rami-Porta R. The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. Journal of Thoracic Oncology. In press. PMID: 28461257. https://www.ncbi.nlm.nih.gov/pubmed/28461257
Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri A. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2016 Dec 22. pii: S0140-6736(16)31594-X. PMID: 28017406. https://www.ncbi.nlm.nih.gov/pubmed/?term=28017406
Jethava Y, Mitchell A, Epstein J, Zangari M, Yaccoby S, Tian E, Waheed S, Khan R, Papanikolaou X, Grazziutti M, Cottler-Fox M, Petty N, Steward D, Panozzo S, Bailey C, Hoering A, Crowley J, Sawyer J, Morgan G, Barlogie B, van Rhee F. Adverse metaphase cytogenetics can be overcome by adding bortezomib and thalidomide to fractionated melphalan transplants. Clin Cancer Res. 2016 Nov 3. pii: clincanres.2620.2015. PMID: 27810902. https://www.ncbi.nlm.nih.gov/pubmed/?term=27810902
Pedersen EA, Menon R, Bailey KM, Thomas DG, Van Noord RA, Tran J, Wang H, Qu P, Hoering A, Fearon ER, Chugh R, Lawlor ER. Activation of Wnt/beta-catenin in Ewing sarcoma cells antagonizes EWS/ETS function and promotes phenotypic transition to more metastatic cell states. Cancer Res. 2016 Jun 30. pii: canres.3422.2015. [Epub ahead of print] PMID: 27364557. https://www.ncbi.nlm.nih.gov/pubmed/?term=27364557
Pedersen EA, Menon R, Bailey KM, Thomas DG, Van Noord RA, Tran J, Wang H, Qu PP, Hoering A, Fearon ER, Chugh R, Lawlor ER (2016 Sept 1). Activation of Wnt/β-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States. Cancer Res. 76(17):5040-53. doi: 10.1158/0008-5472.CAN-15-3422. Epub 2016 Jun 30. PMID: 27364557. https://www.ncbi.nlm.nih.gov/pubmed/?term=27364557
Schinke C, Hoering A, Hongwei W, Carlton V, Thanandrarajan S, Deshpande S, Patel P, Molnar G, Susanibar S, Mohan M, Mathur P, Radhakrishnan M, Hoque S, Jo kamimoto J, Grazziutti M, van Rhee F, Zangari M, Insuasti-Beltran G, Alapat D, Post G, Yaccoby S, Epstein J, Rasche L, Johnson S, Moorhead M, Willis T, Barlogie B, Walker B, Weinhold N, Davies FE, Morgan GJ (2016). The Prognostic Value of the Depth of Response in Multiple Myeloma Depends on the Time of Assessment, Risk Status and Molecular Subtype. Submitted to Haematologica – under revision.
Nicholson AG, Chansky K, Crowley J, Beyruti R, Kubota K, Turrisi A, Eberhardt WE, van Meerbeeck J, Rami-Porta R; Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions; Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016 Mar; 11 (3):300-11. doi: 10.1016/j.jtho.2015.10.008. Epub 2015 Dec 24. PMID: 26723244. https://www.ncbi.nlm.nih.gov/pubmed/?term=26723244
Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016 Jan; 11 (1):39-51. doi: 10.1016/j.jtho.2015.09.009. PMID: 26762738. https://www.ncbi.nlm.nih.gov/pubmed/?term=26762738
Crowley JJ. IBS Past Presidents: Norman Breslow. Biometric Bulletin. 2016 Jan-Mar; 33(1).
Goodman PJ, Tangen CM, Darke AK, Arnold KB, Hartline J, Yee M, Anderson K, Caban-Holt A, Christen WG, Cassano PA, Lance P, Klein EA, Crowley JJ, Minasian LM, Meyskens FL. Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial. Trials. 2016 Aug 12; 17:400. doi: 10.1186/s13063-016-1524-9. PMID: 27519183; PMCID: PMC4983010. https://www.ncbi.nlm.nih.gov/pubmed/?term=27519183
Valdivieso M, Bussalleu A, Sexton R, Boehnke K, Osorio S, Novoa Reyes I, Crowley JJ, Goodman GE, Baker LH, Xi C. Clinical, Epidemiologic, and Genomic Studies (SWOG S1119) of Helicobacter Pylori in Lima, Peru: Role of Contaminated Water. J Cancerol. 2016; 2:52-63
Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shinohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA. PD-1 Blockade with Pembrolizumab in Advances Merkel-Cell Carcinoma. N Engl J Med. 2016 Apr 19; DOI: 10.1056/NEJMoa1603702. PMID: 27093365. https://www.ncbi.nlm.nih.gov/pubmed/27093365
Detterbeck FC, Chansky K, Groome P, Bolejack V, Crowley J, Shemanski L, Kennedy C, Krasnik M, Peake M, Rami-Porta R; IASLC Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions. The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2016 Sep;11 (9):1433-46. PMID: 27448762. https://www.ncbi.nlm.nih.gov/pubmed/27448762
Fredlund P, Hillson J, Gray T, Shemanski L, Dimitrova D, Srinivasan S. Peginterferon Lambda-1a Is Associated with a Low Incidence of Autoimmune Thyroid Disease in Chronic Hepatitis C. J Interferon Cytokine Res. 2015 Nov;35(11):841-3. doi: 10.1089/jir.2014.0233. PMID: 26376344. https://www.ncbi.nlm.nih.gov/pubmed/26376344
Rice D, Chansky K, Nowak A, Pass H, Kindler H, Shemanski L, Opitz I, Call S, Hasegawa S, Kernstine K, Atinkaya C, Rea F, Nafteux P, Rusch VW; Mesothelioma Domain of the IASLC Staging and Prognostic Factors Committee, advisory boards and participating institutions. J Thorac Oncol. 2016 Dec;11 (12):2100-2111. doi: 10.1016/j.jtho.2016.09.121.
Nowak AK, Chansky K, Rice DC, Pass HI, Kindler HL, Shemanski L, Billé A, Rintoul RC, Batirel HF, Thomas CF, Friedberg J, Cedres S, de Perrot M, Rusch VW; Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions. J Thorac Oncol. 2016 Dec;11(12):2089-2099. doi: 10.1016/j.jtho.2016.08.147. PMID: 27687963. https://www.ncbi.nlm.nih.gov/pubmed/27687963
Rusch VW, Chansky K, Kindler HL, Nowak AK, Pass HI, Rice DC, Shemanski L, Galateau-Sallé F, McCaughan BC, Nakano T, Ruffini E, van Meerbeeck JP, Yoshimura M; IASLC Staging and Prognostic Factors Committee, advisory boards, and participating institutions. J Thorac Oncol. 2016 Dec;11(12):2112-2119. doi: 10.1016/j.jtho.2016.09.124. PMID: 27687962. https://www.ncbi.nlm.nih.gov/pubmed/?term=27687962
Tosteson AN, Beaber EF, Tiro J, Kim J, McCarthy AM, Quinn VP, Doria-Rose VP, Wheeler CM, Barlow WE, Bronson M, Garcia M, Corley DA, Haas JS, Halm EA, Kamineni A, Rutter CM, Tosteson TD, Trentham-Dietz A, Weaver DL; PROSPR consortium. Variation in screening abnormality rates and follow-up of breast, cervical and colorectal cancer screening within the PROSPR Consortium. J Gen Intern Med. 2016; 31:372-9. PMID: 26658934; PMCID: PMC4803707. https://www.ncbi.nlm.nih.gov/pubmed/?term=26658934
Hershman DL, Unger JM, Wright JD, Ramsey S, Till C, Tangen CM, Barlow WE, Blanke C, Thompson IM, Hussain M. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol. 2016; 2:453-61. PMID: 26720308. PMCID: PMC4852142. https://www.ncbi.nlm.nih.gov/pubmed/?term=26720308
McCarthy AM, Kim JJ, Beaber EF, Zheng Y, Burnett-Hartman A, Chubak J, Ghai NR, McLerran D, Breen N, Conant EF, Geller BM, Green BB, Klabunde CN, Inrig S, Skinner CS, Quinn VP, Haas JS, Schnall M, Rutter CM, Barlow WE, Corley DA, Armstrong K, Doubeni CA; PROSPR consortium. Follow-Up of Abnormal Breast and Colorectal Cancer Screening by Race/Ethnicity. Am J Prev Med. 2016; 51:507-12. PMID: 27132628; PMCID: PMC5030116. https://www.ncbi.nlm.nih.gov/pubmed/?term=27132628
Unger JM, Barlow WE, Ramsey SD, LeBlanc M, Blanke CD, Hershman DL. The scientific impact of positive and negative Phase 3 cancer clinical trials. JAMA Oncol. 2016; 2:875-81. PMID: 26967260; PMCID: PMC4945370. https://www.ncbi.nlm.nih.gov/pubmed/?term=26967260
Conant EF, Beaber EF, Sprague BL, Herschorn SD, Weaver DL, Onega T, Tosteson AN, McCarthy AM, Poplack SP, Haas JS, Armstrong K, Schnall MD, Barlow WE. Breast cancer screening using tomosynthesis in combination with digital mammography compared to digital mammography alone: a cohort study within the PROSPR consortium. Breast Cancer Res Treat. 2016; 156:109-16. PMID: 26931450. https://www.ncbi.nlm.nih.gov/pubmed/?term=26931450
Hertz DL, Barlow WE, Kidwell KM, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Livingston RB, Gralow J, Hayes DF, Hortobagyi GN, Mehta RS, Rae JM. Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226. Br J Clin Pharmacol. 2016; 81:1134-41. PMID: 26859101. https://www.ncbi.nlm.nih.gov/pubmed/?term=26859101
Unger JM, Till C, Thompson IM Jr, Tangen CM, Goodman PJ, Wright JD, Barlow WE, Ramsey SD, Minasian LM, Hershman DL. Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial. JNCI. 2016; 108(12). PMID: 27565902. https://www.ncbi.nlm.nih.gov/pubmed/?term=27565902
Schott AF, Barlow WE, Van Poznak CH, Hayes DF, Moinpour CM, Lew DL, Dy PA, Keller ET, Keller JM, Hortobagyi GN. Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Res Treat. 2016; 159:87-95. PMID: 27475087; PMCID: PMC5021222. https://www.ncbi.nlm.nih.gov/pubmed/?term=27475087
Sprague BL, Conant EF, Onega T, Garcia MP, Beaber EF, Herschorn SD, Lehman CD, Tosteson AN, Lacson R, Schnall MD, Kontos D, Haas JS, Weaver DL, Barlow WE; PROSPR Consortium. Variation in Mammographic Breast Density Assessments Among Radiologists in Clinical Practice: A Multicenter Observational Study. Ann Intern Med. 2016; 165:457-464. PMID: 27428568; PMCID: PMC5050130. https://www.ncbi.nlm.nih.gov/pubmed/?term=27428568
Nahleh ZA, Barlow WE, Hayes DF, Schott AF, Gralow JR, Sikov WM, Perez EA, Chennuru S, Mirshahidi HR, Corso SW, Lew DL, Pusztai L, Livingston RB, Hortobagyi GN. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat. 2016; 158:485-95. PMID: 27393622; PMCID: PMC4963434. https://www.ncbi.nlm.nih.gov/pubmed/?term=27393622
Hershman DL, Till C, Wright JD, Awad D, Ramsey SD, Barlow WE, Minasian LM, Unger J. Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. J Clin Oncol. 2016; 34:3014-22. PMID: 27325863; PMCID: PMC5012713. https://www.ncbi.nlm.nih.gov/pubmed/?term=27325863
Beaber EF, Tosteson AN, Haas JS, Onega T, Sprague BL, Weaver DL, McCarthy AM, Doubeni CA, Quinn VP, Skinner CS, Zauber AG, Barlow WE. Breast cancer screening initiation after turning 40 years of age within the PROSPR consortium. Breast Cancer Res Treat. 2016; 160:323-331. PMID: 27665586. https://www.ncbi.nlm.nih.gov/pubmed/?term=27665586
Unger JM, Barlow WE, Hershman DL. Measuring the real clinical impact of randomized clinical trials in oncology-Reply: Beyond citation counts. JAMA Oncol. 2016; 2:1511. PMID: 27355398. https://www.ncbi.nlm.nih.gov/pubmed/?term=27355398
Pedersen EA, Menon R, Bailey KM, Thomas DG, Van Noord RA, Tran J, Wang H, Qu PP, Hoering A, Fearon ER, Chugh R, Lawlor ER. Activation of Wnt/β-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States. Cancer Res. 2016 Sep 1;76(17):5040-53. doi: 10.1158/0008-5472.CAN-15-3422. Epub 2016 Jun 30. PMID: 27364557. https://www.ncbi.nlm.nih.gov/pubmed/?term=27364557
Nicholson AG, Groome P, Mitchell A, Bolejack V. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11:39-51. PMID: 26762738. https://www.ncbi.nlm.nih.gov/pubmed/?term=26762738
Nicholson AG, Chansky K, Crowley J, Beyruti R, Kubota K, Turrisi A, Eberhardt WE, van Meerbeeck J, Rami-Porta R. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016; 11:300-11.
Detterbeck FC, Nicholson AG, Franklin WA, Marom EM, Travis WD, Girard N, Arenberg DA, Bolejack V, Donington JS, Mazzone PJ, Tanoue LT, Rusch VW, Crowley J, Asamura H, Rami-Porta R. The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. J Thorac Oncol. 2016; 11:639-50. PMID: 26940528. https://www.ncbi.nlm.nih.gov/pubmed/?term=26940528
Detterbeck FC, Nicholson AG, Franklin WA, Marom EM, Travis WD, Girard N, Arenberg DA, Bolejack V, Donington JS, Mazzone PJ, Tanoue LT, Rusch VW, Crowley J, Asamura H, Rami-Porta R. The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. J Thorac Oncol. 2016; 11:639-50. PMID: 26940528. https://www.ncbi.nlm.nih.gov/pubmed/?term=26940528
Detterbeck FC, Bolejack V, Arenberg DA, Crowley J, Donington JS, Franklin WA, Girard N, Marom EM, Mazzone PJ, Nicholson AG, Rusch VW, Tanoue LT, Travis WD, Asamura H, and Rami-Porta R. The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016; 11:681-92. PMID:26944304. https://www.ncbi.nlm.nih.gov/pubmed/26944304
Nowak AK, Chansky K, Rice DC, Pass HI, Kindler HL, Shemanski L, Billé A, Rintoul RC, Batirel HF, Thomas CF, Friedberg J, Cedres S, de Perrot M, and Rusch VW. The IASLC mesothelioma staging project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. J Thorac Oncol. 2016;11:2089–2099. PMID: 27687963. https://www.ncbi.nlm.nih.gov/pubmed/27687963
Rice D, Chansky K, Nowak A, Pass H, Kindler H, Shemanski L, Opitz I, Call S, Hasegawa S, Kernstine K, Atinkaya C, Rea F, Nafteux P, and Rusch VW. The IASLC mesothelioma staging project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. J Thorac Oncol. 2016;11:2100–2111. PMID: 27687964. https://www.ncbi.nlm.nih.gov/pubmed/27687964
Andreotti G, Katz M, Hoering A, Van Ness B, Crowley J, Morgan G, Hoover RN, Baris D, Durie B. Risk of multiple myeloma in a case-spouse study. Leuk Lymphoma. 2015 Nov 16:1-10. PMID: 26422532. https://www.ncbi.nlm.nih.gov/pubmed/?term=26422532
Stein CK, Qu P, Epstein J, Buros A, Rosenthal A, Crowley J, Morgan G, Barlogie B. Removing batch effects from purified plasma cell gene expression microarrays with modified ComBat. BMC Bioinformatics. 2015 Feb 25;16:63. doi: 10.1186/s12859-015-0478-3. PMID: 25887219; PMCID: PMC4355992. https://www.ncbi.nlm.nih.gov/pubmed/?term=25887219
Khan R, Dhodapkar M, Rosenthal A, Heuck C, Papanikolaou X, Qu P, van Rhee F, Zangari M, Jethava Y, Epstein J, Yaccoby S, Hoering A, Crowley J, Petty N, Bailey C, Morgan G, Barlogie B. Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). Haematologica. 2015 May 28. pii: haematol.2015.124651. [Epub ahead of print] PMID: 26022710. https://www.ncbi.nlm.nih.gov/pubmed/?term=26022710
Qu P, Barlogie B, Crowley J. Using a latent class model to refine risk stratification in multiple myeloma. Stat Med. 2015 Sep 20;34(21):2971-80. doi: 10.1002/sim.6557. Epub 2015 Jun 17. PMID: 26084662. https://www.ncbi.nlm.nih.gov/pubmed/?term=26084662
Khan R, Dhodapkar M, Rosenthal A, Heuck C, Papanikolaou X, Qu P, van Rhee F, Zangari M, Jethava Y, Epstein J, Yaccoby S, Hoering A, Crowley J, Petty N, Bailey C, Morgan G, and Barlogie B (2015). Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). Haematologica, 100(9): 1214-21, doi: 10.3324/haematol. 2015.124651. PMID: 26022710. https://www.ncbi.nlm.nih.gov/pubmed/26022710
Qu P, Barlogie B, Crowley J. Using a latent class model to refine risk stratification in multiple myeloma. Stat Med. 2015 Sep 20; 34 (21):2971-80. doi: 10.1002/sim.6557. Epub 2015 Jun 17. PMID: 26084662. https://www.ncbi.nlm.nih.gov/pubmed/?term=26084662
Rami-Porta R, Bolejack V, Crowley J, Ball D, Kim J, Lyons G, Rice T, Suzuki K, Thomas CF Jr, Travis WD, Wu YL; IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2015 Jul; 10(7):990-1003. doi: 10.1097/JTO.0000000000000559. PMID: 26134221. https://www.ncbi.nlm.nih.gov/pubmed/?term=26134221
Dhodapkar MV, Sexton R, Das R, Dhodapkar KM, Zhang L, Sundaram R, Soni S, Crowley JJ, Orlowski RZ, Barlogie B. Prospective analysis of antigen-specific immunity, stem cell antigens and immune checkpoints in monoclonal gammopathy. Blood. 2015 Oct 14. pii: blood-2015-03-632919. [Epub ahead of print] PMID: 26468228. https://www.ncbi.nlm.nih.gov/pubmed/?term=26468228
Eberhardt W, Mitchell A, Crowley JJ, Kondo H, Kim Y, Turrisi A, Goldstraw P, Rami-Porta R; IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2015 Nov; 10(11):1515-1522. PMID: 26536193. https://www.ncbi.nlm.nih.gov/pubmed/?term=26536193
Asamura H, Chansky K, Crowley J, Goldstraw P, Rusch VW, Vansteenkiste JF, Watanabe H, Wu YL, Zielinski M, Ball D, Rami-Porta R; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members, and Participating Institutions. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2015 Dec; 10 (12):1675-84. doi: 10.1097/JTO.0000000000000678. PMID: 26709477. https://www.ncbi.nlm.nih.gov/pubmed/?term=26709477
Ramsey SD, Henry NL, Gralow JR, Mirick DK, Barlow W, Etzioni R, Mummy D, Thariani R, Veenstra DL. Tumor Marker Usage and Medical Care Costs Among Older Early-Stage Breast Cancer Survivors. J Clin Oncol. 2015 Jan 10;33(2):149-55. doi: 10.1200/JCO.2014.55.5409. Epub 2014 Oct 20. PMID: 25332254; PMCID: PMC4279234. https://www.ncbi.nlm.nih.gov/pubmed/?term=25332254
Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS; POEMS/S0230 Investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015 Mar 5;372(10):923-32. doi: 10.1056/NEJMoa1413204. PMID: 25738668; PMCID: PMC4405231. https://www.ncbi.nlm.nih.gov/pubmed/?term=25738668
Tilan JU, Krailo M, Barkauskas DA, Galli S, Mtaweh H, Long J, Wang H, Hawkins K, Lu C, Jeha D, Izycka-Swieszewska E, Lawlor ER, Toretsky JA, Kitlinska JB. --- Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survival. --- Cancer. 2015 Mar 1;121(5):697-707. doi: 10.1002/cncr.29090. Epub 2014 Nov 11. PMID: 25387699. https://www.ncbi.nlm.nih.gov/pubmed/25387699
Rami-Porta R, Bolejack V, Crowley J, Ball D, Kim J, Lyons G, Rice T, Suzuki K, Thomas CF Jr, Travis WD, Wu YL. Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2015;10:990-1003. PMID: 26134221. https://www.ncbi.nlm.nih.gov/pubmed/?term=26134221
Asamura H, Chansky K, Crowley J, Goldstraw P, Rusch VW, Vansteenkiste JF, Watanabe H, Wu YL, Zielinski M, Ball D, Rami-Porta R. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer.. J Thorac Oncol. 2015; 10:1675-1684. PMID: 26709477. https://www.ncbi.nlm.nih.gov/pubmed/?term=26709477
Eberhardt WE, Mitchell A, Crowley J, Kondo H, Kim YT, Turrisi A 3rd, Goldstraw P, Rami-Porta R. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer.. J Thorac Oncol. 2015;10:1515–22. PMID: 26536193. https://www.ncbi.nlm.nih.gov/pubmed/?term=26536193
Crowley J, Qu P and Barlogie B (2014). Ethical issues in getting it right: using big data to determine medical treatment. In JSM Proceedings, Committee on professional ethics. Alexandria, VA: American Statistical Association. 56-67.
Heuck CJ, Qu P, van Rhee F, Waheed S, Usmani SZ, Epstein J, Zhang Q, Edmondson R, Hoering A, Crowley J and Barlogie B (2014). Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma. Leukemia, 28(12): 2410-3. doi: 10.1038/leu.2014.232. PMID: 25079174. https://www.ncbi.nlm.nih.gov/pubmed/?term=25079174
Unger JM, Hershman DL, Martin D, Etzioni RB, Barlow WE, LeBlanc M, Ramsey SR. The diffusion of docetaxel in patients with metastatic prostate cancer. J Natl Cancer Inst. 2014 Dec 24;107(2). pii: dju412. doi: 10.1093/jnci/dju412. Print 2015 Feb. PMID: 25540245; PMCID: PMC4326312. https://www.ncbi.nlm.nih.gov/pubmed/?term=25540245
Rami-Porta R, Bolejack V, Giroux DJ, Chansky K, Crowley J, Asamura H, and Goldstraw P. The IASLC Lung Cancer Staging Project: the new database to inform the eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2014; 9:1618–1624. PMID: 25436796. https://www.ncbi.nlm.nih.gov/pubmed/25436796
Pass HI, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, Asamura H, Waller D, Edwards J, Weder W, Hoffmann H, van Meerbeeck JP, and Rusch VW. Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee. J Thorac Oncol. 2014; 9:856–864. PMID: 24807157. https://www.ncbi.nlm.nih.gov/pubmed/?term=24807157
Nicholson A, Detterbeck FC, Marino M, Kim J, Stratton K, Giroux D, Asamura H, John Crowley J, Falkson C, PL, Giaccone G, Huang J, Kondo K, Lucchi M, Marom E, Okumura M, Ruffini E, and Van Schil P. The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposals for the T component for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors. J Thor Oncol 2014;9:S73–S80.
Kondo K, Van Schil P, Detterbeck FC, Okumura M, Stratton K, Giroux D, Asamura H, John Crowley J, Falkson C, PL, Giaccone G, Huang J, Kim J, Lucchi M, Marino M, Marom E, Nicholson AG, and Ruffini E. The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposals for the N and M Components for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors. J Thor Oncol 2014;9 S81–S87. PMID: 25396316. https://www.ncbi.nlm.nih.gov/pubmed/?term=25396316
Usmani SZ, Hoering A. Heterogeneity of outcome with single-agent carfilzomib: all relapsed/refractory myelomas are not created equal. Leukemia. 2013 Dec;27(12):2269-71. PMID: 24326595. https://www.ncbi.nlm.nih.gov/pubmed/?term=24326595
Hoering A, Mitchell A, LeBlanc M, Crowley J. Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents. Clin Trials. 2013;10(3):422-9. PMID: 23529697; PMCID: PMC3744092. https://www.ncbi.nlm.nih.gov/pubmed/?term=23529697
Unger JM, Hershman DL, Albain KS, Moinpour CM, Petersen JA, Burg K, Crowley JJ. Patient income level and cancer clinical trial participation. J Clin Oncol. 2013 Feb 10;31(5):536-42. doi: 10.1200/JCO.2012.45.4553. PMID: 23295802; PMCID: PMC3565180. https://www.ncbi.nlm.nih.gov/pubmed/?term=23295802
Kryscio RJ, Abner EL, Schmitt FA, Goodman PJ, Mendiondo M, Caban-Holt A, Dennis BC, Mathews M, Klein EA, Crowley JJ. A Randomized Controlled Alzheimer's Disease Prevention Trial's Evolution into an Exposure Trial: The PREADViSE Trial. J Nutr Health Aging. 2013;17(1):72-5. doi: 10.1007/s12603-012-0083-3. PMID: 23299383. https://www.ncbi.nlm.nih.gov/pubmed/?term=23299383%5D
Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, Brown T, Bartel T, Anaissie E, van Rhee F, Barlogie B. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013 Mar 7;121(10):1819-23. doi: 10.1182/blood-2012-08-451690. PMID: 23305732; PMCID: PMC3591801. https://www.ncbi.nlm.nih.gov/pubmed/?term=23305732
Detterbeck F, Asamura H, Crowley J, Falkson C, PL, Giaccone G, Giroux D, Huang J, Kim J, Kondo K, Lucchi M, Marino M, Marom E, Nicholson AG, Okumura M, Ruffini E, Van Schil P, and Stratton K. The IASLC/ITMIG thymic malignancies staging project: development of a stage classification for thymic malignancies. J Thorac Oncol 2013;8:1467–1473. PMID: 24389429. https://www.ncbi.nlm.nih.gov/pubmed/24389429
Chien JW, Zhang XC, Fan W, Wang H, Zhao LP, Martin PJ, Storer BE, Boeckh M, Warren EH, Hansen JA. Evaluation of published single nucleotide polymorphisms associated with acute GVHD. Blood. 2012 May 31;119(22):5311-9. PMID: 22282500; PMCID: PMC3369619. https://www.ncbi.nlm.nih.gov/pubmed/?term=22282500
Goodman, K., Krueger, J., & Crowley, J. (2012). The automatic clinical trial: Leveraging the electronic medical record in multisite cancer clinical trials. Current Oncology Reports, 14(6), 509-518, doi: 10.1007/s11912-012-0262-8. PubMed: PMCID: PMC3490046. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3490046/
Rusch VW, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, Pass H, Asamura H, Waller D, Edwards J, Weder W, Hoffmann H, and van Meerbeeck JP. Initial analysis of the International Association for the Study of Lung Cancer mesothelioma database. J Thorac Oncol. 2012;7: 1631–1639. PMID: 23070243. https://www.ncbi.nlm.nih.gov/pubmed/23070243
Rusch VW, Giroux D. Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database. Ann Cardiothorac Surg. 2012;1:438-48. PMID: 23977534. https://www.ncbi.nlm.nih.gov/pubmed/?term=PMC3741785
According to the publisher, the Handbook Second Edition "is the best single source for up-to-date statistical approaches to research in clinical medicine."
More than just an update of the handbook that became the gold standard, this third edition brings you fully into the genomic era of medicine.
Clinical Trials in Oncology emphasizes the importance of proper study, design and data management, and explains why communication and partnership between statisticians and clinicians are vital to the conduct of a successful trial.
Clinical Trials in Oncology is written for research oncologists and graduate students in biostatistics. It also provides essential information for statisticians involved with cancer clinical trials.